Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy?-Reference-Cited by-同舟云学术

Is targeting of CD47-SIRPα enough for treating hematopoietic malignancy?

Published:2012-05-03 Issue:18 Volume:119 Page:4333-4334
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zhao Xi Wen¹,Kuijpers Taco W.²,van den Berg Timo K.¹

Affiliation:

1. Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

2. Sanquin Research, and Landsteiner Laboratory, Academic Medical Center, Emma Children's Hospital, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/119/18/4333/1352746/zh801812004333.pdf

Reference9 articles.

1. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.;Chao;Blood,2011

2. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.;Chao;Cell,2010

3. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.;Majeti;Cell,2009

4. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.;Jaiswal;Cell,2009

5. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.;Chao;Cancer Res,2011

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions;Cancer Cell;2023-12

2. CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity;Nature Immunology;2023-11-09

3. Cancer immunotherapies: advances and bottlenecks;Frontiers in Immunology;2023-08-24

4. The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions;2023-06-29

5. Is the new angel better than the old devil? Challenges and opportunities in CD47- SIRPα-based cancer therapy;Critical Reviews in Oncology/Hematology;2023-04